Ignite Creation Date:
2025-12-24 @ 7:41 PM
Ignite Modification Date:
2025-12-30 @ 2:33 PM
Study NCT ID:
NCT05374603
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-27
First Post:
2022-04-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-11-23
Start Date Type:
ACTUAL
Primary Completion Date:
2025-08-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-08-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-04-29
First Submit QC Date:
None
Study First Post Date:
2022-05-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-25
Last Update Post Date:
2025-04-27
Last Update Post Date Type:
ACTUAL